Cargando…

EHMTI-0102. Prospective analysis of the use of onabotulinumtoxina (botox®) In the treatment of chronic migraine; real-life data in 299 patients from hull, UK

Detalles Bibliográficos
Autores principales:	Khalil, M, Zafar, H, Quarshie, V, Ahmed, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2014
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182226/ http://dx.doi.org/10.1186/1129-2377-15-S1-G19

Ejemplares similares

Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK
por: Khalil, Modar, et al.
Publicado: (2014)

EHMTI-0090. Botox in the prevention of chronic migraine; comparing NICE criteria versus hull criteria for evaluating responder rate
por: Zafar, H, et al.
Publicado: (2014)

Hull prospective analysis of Botulinum Toxin type A (Botox) use in the treatment of chronic migraine
por: Ahmed, F, et al.
Publicado: (2013)

EHMTI-0223. Botox in the prevention of chronic migraine; 18-months follow up outcome in 67 patients
por: Khalil, M, et al.
Publicado: (2014)

EHMTI-0192. Onabotulinumtoxina prophylaxis in chronic migraine utilization and patient characteristics: observational study in the European Union
por: Matharu, M, et al.
Publicado: (2014)

Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review
por: Shaterian, Negar, et al.
Publicado: (2022)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks
por: Oterino, A., et al.
Publicado: (2011)

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

Early development history of Botox (onabotulinumtoxinA)
por: Scott, Alan B., et al.
Publicado: (2023)

The pluripotential evolution and journey of Botox (onabotulinumtoxinA)
por: Brin, Mitchell F., et al.
Publicado: (2023)

Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2020)

EHMTI-0326. OnabotulinumtoxinA for the treatment of chronic paroxysmal hemicrania: a case report
por: Dolezil, D
Publicado: (2014)

Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data
por: Lanteri-Minet, Michel, et al.
Publicado: (2022)

EHMTI-0146. Topiramate in migraine prevention
por: Ristic, S, et al.
Publicado: (2014)

EHMTI-0191. A novel approach for the treatment of cluster headache – onabotulinumtoxina block of the sphenopalatine ganglion
por: Bratbak, D, et al.
Publicado: (2014)

EHMTI-0133. Does medication overuse matter? Response to botulinum toxin type A in chronic migraine in patients with or without medication overuse
por: Zafar, H, et al.
Publicado: (2014)

Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Lowe, Nicholas, et al.
Publicado: (2023)

EHMTI-0334. Chronic migraine in young age: clinical characteristics in a prospective chronic migraine registry
por: Ruiz, M, et al.
Publicado: (2014)

EHMTI-0086. Pure mestrual vestibular migraine
por: Mostardini, C, et al.
Publicado: (2014)

EHMTI-0049. Headache, migraine and epileptic seizures
por: Gligic, N, et al.
Publicado: (2014)

EHMTI-0089. Relationship of sleep bruxism and migraine
por: Kato, M, et al.
Publicado: (2014)

EHMTI-0024. The typical duration of migraine aura: a prospective diary-based study
por: Viana, M, et al.
Publicado: (2014)

EHMTI-0111. Intra-variability of migraine attacks features
por: Viana, M, et al.
Publicado: (2014)

EHMTI-0122. Serum micrornas as potential biomarkers of migraine
por: Andersen, HH, et al.
Publicado: (2014)

EHMTI-0107. Treatment of migraine in Croatia, year 2013
por: Cvetkovic, V Vukovic, et al.
Publicado: (2014)

EHMTI-0358. Improved chronic migraine after DTMS
por: Scatena, P, et al.
Publicado: (2014)

EHMTI-0348. Refractive errors in patients with migraine headache
por: Gunes, A, et al.
Publicado: (2014)

EHMTI-0050. Systemic and cerebral endothelial function in migraine
por: Zaletel, M, et al.
Publicado: (2014)

EHMTI-0189. Tryptophan-kynurenine metabolism in migraine patients
por: Majláth, Z, et al.
Publicado: (2014)

EHMTI-0070. Effect of occlusal sprint in migraine patients
por: Takeuchi, M, et al.
Publicado: (2014)

EHMTI-0374. Gene-based pleiotropy across migraine with and migraine without aura
por: Nyholt, D, et al.
Publicado: (2014)

EHMTI-0230. Characteristics of menstrual and nonmenstrual migraine attacks in women with menstrual migraine
por: Vetvik, KG, et al.
Publicado: (2014)

Long-Term Management of Migraine With OnabotulinumtoxinA (Botox) vs Calcitonin Gene-Related Peptide Antibodies (Anti-CGRP)
por: Pallapothu, Manoj R, et al.
Publicado: (2023)

OnabotulinumtoxinA (Botox) in the Treatment of Crow’s Feet Lines in Japanese Subjects
por: Harii, Kiyonori, et al.
Publicado: (2017)

Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Jean, et al.
Publicado: (2023)

Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Scott, Alan B., et al.
Publicado: (2023)

Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Esquenazi, Alberto, et al.
Publicado: (2023)

Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Jankovic, Joseph, et al.
Publicado: (2023)

EHMTI-0249. Headache attributed to hypertension in chronic migraine patients
por: Grosu, O, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kp904nu5tqdos3ink5nkci0fdr